- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02897986
Undersøgelse af en kombination af propranolol (HEMANGIOL®) og oral metronomisk vinorelbin (NAVELBINE®) til børn og teenagere med refraktære/tilbagevendende solide tumorer (PROVIN)
PROVIN : Etude de Phase I d'Une Combinaison Orale de Propranolol et de Vinorelbine (Navelbine®) métronomique Pour Les Tumeurs en Rechutes ou réfractaires de l'Enfant et de l'Adolescent.
Cancer remains the first cause of death due to disease in children and adolescents despite important progress and 70% of the survivors present sequelae. It is therefore mandatory to generate new and preferably less toxic treatment strategies relying on new anticancer agents, and/or new combinations or schedules of administered compounds.
Metronomic chemotherapy (MC) consists in administrating low doses of anticancer agents on a daily/weekly basis. MC has been showed to be a safe and effective way to administer chemotherapy to obtain anti-cancer effects through anti-angiogenic and pro-imune effects.
Drug repositioning consist in using non-anticancer drug for which anti-cancer properties have been unveiled. Propranolol is a non selective beta-blocker initially used to treat hypertension but recently its anticancer properties have been discovered. The place of Betablockers as anticancer agents is supported by both preclinical and epidemiologic data. The investigators have showed that the use of betablockers could sensitize breast cancer, angiosarcoma and neuroblastoma to chemotherapy in vitro and in vivo at least in part via an anti-angiogenic mechanism. There are currently 12 clinical trials evaluating prospectively their potential in adults with cancer but none in children so far.
The Objective is to determine the Maximal Tolerated Dose (MTD) of a combination of oral metronomic vinorelbine and daily oral propranolol. This study is a phase I trial with a "rolling six" design and a dose escalation with thrice weekly oral vinorelbine only plus addition of daily oral propranolol after completion of the first cycle. PK analysis of vinorelbine and propranolol will be performed. Once the recommended dose of the combination established 4 extension cohorts of 9 patients will be added Potential biomarkers (such as beta-adrenergic receptors on the tumours, B-tubulin isotypes in the tumour) will also be evaluated.
This will provide a well tolerated, all oral combination for patients with refractory/relapsing tumours. This combination could also be then proposed as a maintenance for instance in patients with rhabdomyosarcoma or neuroblastoma.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Nicolas ANDRE, Professor
- E-mail: nicolas.andre@ap-hm.fr
Studiesteder
-
-
-
Marseille, Frankrig, 13005
- Rekruttering
- Assistance Publique Hôpitaux de Marseille
-
Kontakt:
- Nicolas ANDRE, Professor
- E-mail: nicolas.andre@ap-hm.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed malignant solid tumour and refractory low grade gliomas and desmoids tumours.
- Relapsed or refractory tumours after at least one line of treatment (patients can have been previously treated with oral or IV vinorelbine with a weekly schedule)
- Measurable targets
- Lansky Score > 70 or score OMS < 2.
- Life expectancy > 6 months.
- Adequate haematological function: neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L
- Creatinine< 1.5X normal value for the age or clearance >70 ml/mn/1.73 m2
- Liver function: Bilirubin < 3N and ALAT and ASAT < 4 N).
- Other organ toxicity < Grade 2 according to NCI-CTC version 4.0
- No active infection
Exclusion Criteria:
-
Absence of a wash out period of:
- 21 days in case of previous chemotherapy or targeted therapy (reduced to 2 weeks in case of treatment vincristine or prolonged to 6 weeks in case of treatment with nitrosurea agents)
- 6 weeks in case of prior radiotherapy of the target lesions
-
Peripheral neuropathy > grade 2
-
contra-indication to Propranolol (i.e. asthma, bradycardia, hypotension, decreased SF, ECG-anomalies)
-
Pregnancy or breast feeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: patienter med refraktære/tilbagevendende solide tumorer
|
Administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
antal patienter med grad 3 toksicitet
Tidsramme: 28 dage
|
28 dage
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Urielle Desalbres, Assistance Publique Hôpitaux de Marseille
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2016-06
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .